Matthew G. Stilwell

1.2k citations

20 papers · 1.0k indexed · h-index 15

Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria 13
Applied Microbiology and Biotechnology top 1%
- Antibiotic Use and Resistance 3
Clinical Biochemistry top 1%
- Bacterial Identification and Susceptibility Testing 10
Infectious Diseases top 5%
- Antimicrobial Resistance in Staphylococcus 8
Pharmacology top 5%
- Antibiotics Pharmacokinetics and Efficacy 11
Epidemiology
- Pneumonia and Respiratory Infections 8
Public Health, Environmental and Occupational Health
- Streptococcal Infections and Treatments 2
Molecular Biology
- Biochemical and Structural Characterization 1

Co-authors: Ronald N. Jones Thomas R. Fritsche Hélio S. Sader Gary J. Moet Douglas J. Biedenbach Michael J. Dowzicky Rodrigo E. Mendes David M. Johnson
Cited by: Molecular Medicine Applied Microbiology and Biotechnology Clinical Biochemistry
Journals: Diagnostic Microbiology and Infectious Disease (15 papers)International Journal of Antimicrobial Agents (2 papers)Clinical Infectious Diseases (1 paper)
Partner nations: United States Australia Colombia

In The Last Decade

Matthew G. Stilwell

20 papers receiving 963 citations

Peers

Countries citing papers authored by Matthew G. Stilwell

Since Specialization

Citations

This map shows the geographic impact of Matthew G. Stilwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew G. Stilwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew G. Stilwell more than expected).

Fields of papers citing papers by Matthew G. Stilwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew G. Stilwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew G. Stilwell. The network helps show where Matthew G. Stilwell may publish in the future.

Co-authorship network

The 21 scholars most cited alongside Matthew G. Stilwell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew G. Stilwell Line = papers co-authored together Matthew G. Stilwell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains) Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Matthew G. Stilwell	2013	17
2	Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008–2011) International Journal of Antimicrobial Agents ·Hélio S. Sader,Ronald N. Jones,Matthew G. Stilwell,Robert K. Flamm	2013	9
3	Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Michael L. Wilson,Melvin P. Weinstein,Matthew G. Stilwell,Rodrigo E. Mendes	2013	14
4	Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Matthew G. Stilwell,Michael L. Wilson,Rodrigo E. Mendes	2013	19
5	Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections Clinical Infectious Diseases ·César A. Arias,Rodrigo E. Mendes,Matthew G. Stilwell,Ronald N. Jones,Barbara E. Murray	2012	47
6	Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Robert K. Flamm,Hélio S. Sader,Matthew G. Stilwell	2012	9
7	Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997–2007) Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Matthew G. Stilwell,Paul R. Rhomberg,Hélio S. Sader	2009	46
8	In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Jan Bell,Hélio S. Sader,John Turnidge,Matthew G. Stilwell	2009	6
9	Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Thomas R. Fritsche,Hélio S. Sader,Matthew G. Stilwell	2007	20
10	Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Hélio S. Sader,Matthew G. Stilwell,Thomas R. Fritsche	2007	11
11	Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program Antimicrobial Agents and Chemotherapy ·Ronald N. Jones,Matthew G. Stilwell,Patricia A. Hogan,Daniel J. Sheehan	2007	20
12	Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004) Diagnostic Microbiology and Infectious Disease ·Gary J. Moet,Ronald N. Jones,Douglas J. Biedenbach,Matthew G. Stilwell,Thomas R. Fritsche	2006	315
13	Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004) Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Matthew G. Stilwell,Hélio S. Sader,Thomas R. Fritsche,Beth P. Goldstein	2006	48
14	Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003) Diagnostic Microbiology and Infectious Disease ·David M. Johnson,Matthew G. Stilwell,Thomas R. Fritsche,Ronald N. Jones	2006	63
15	Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents Diagnostic Microbiology and Infectious Disease ·Hélio S. Sader,Ronald N. Jones,Matthew G. Stilwell,Michael J. Dowzicky,Thomas R. Fritsche	2005	95
16	Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia Diagnostic Microbiology and Infectious Disease ·Thomas R. Fritsche,Hélio S. Sader,Matthew G. Stilwell,Michael J. Dowzicky,Ronald N. Jones	2005	71
17	Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003) Clinical Microbiology and Infection ·Thomas R. Fritsche,Matthew G. Stilwell,Ronald N. Jones	2005	97
18	Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004) Diagnostic Microbiology and Infectious Disease ·Thomas R. Fritsche,Hélio S. Sader,Matthew G. Stilwell,Michael J. Dowzicky,Ronald N. Jones	2005	56
19	Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002–2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents International Journal of Antimicrobial Agents ·Sudha Pottumarthy,Thomas R. Fritsche,Hélio S. Sader,Matthew G. Stilwell,Ronald N. Jones	2005	24
20	Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones,Michael A. Pfaller,Matthew G. Stilwell	2001	25

About Matthew G. Stilwell

Matthew G. Stilwell is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Clinical Biochemistry, Pharmacology and Infectious Diseases, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (13 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers), Bacterial Identification and Susceptibility Testing (10 papers), Pneumonia and Respiratory Infections (8 papers), Antimicrobial Resistance in Staphylococcus (8 papers), Antibiotic Use and Resistance (3 papers), Streptococcal Infections and Treatments (2 papers) and Biochemical and Structural Characterization (1 paper). The work is most often cited by research in Molecular Medicine (401 citations), Applied Microbiology and Biotechnology (147 citations), Clinical Biochemistry (327 citations), Infectious Diseases (457 citations) and Pharmacology (334 citations). Matthew G. Stilwell has collaborated with scholars based in United States, Australia and Colombia. Frequent co-authors include Ronald N. Jones, Thomas R. Fritsche, Hélio S. Sader, Gary J. Moet, Douglas J. Biedenbach, Michael J. Dowzicky, Rodrigo E. Mendes, David M. Johnson, Paul R. Rhomberg and Beth P. Goldstein. Their work appears in journals such as Diagnostic Microbiology and Infectious Disease, International Journal of Antimicrobial Agents, Clinical Infectious Diseases, Clinical Microbiology and Infection and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact